Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This finding falls in line with numerous analyses that show that PrEP’s benefits are largely not reaching Black gay and bi men.
Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.
However, there is still room for improvement in ensuring a largely indigent population of people with HIV gets access to medical care.
Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.
More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.
With the HIV population aging, it is increasingly at risk of such age-related cancers.
This is according to a study of women 18 to 55 years old and their Framingham cardiovascular risk score based on HIV status.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
At one major St. Louis HIV clinic, only about a third of those indicated for a statin were on one of the heart-disease-preventing drugs.
Following national trends, troubling disparities persist, with Black men who have sex with men less likely to receive PrEP than whites.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.